Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies

J Dermatol. 1993 Sep;20(9):533-9. doi: 10.1111/j.1346-8138.1993.tb01334.x.

Abstract

In this study, we have utilized the human high molecular weight-melanoma associated antigen (HMW-MAA) as a target for active specific immunotherapy with mouse anti-idiotypic (anti-id) monoclonal antibodies (mAb) in patients with malignant melanoma. After having summarized the characteristics of HMW-MAA which account for its selection as a target for immunotherapy, we describe the development and characterization of mouse anti-id mAb MK2-23 which bears the internal image of HMW-MAA. Furthermore, we describe the results of the first clinical trial performed with mouse anti-id mAb MK2-23 in patients with malignant melanoma.

Publication types

  • Clinical Trial

MeSH terms

  • Animals
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibody Formation
  • Antigens, Neoplasm / immunology*
  • Humans
  • Immunotherapy, Active*
  • Melanoma / mortality
  • Melanoma / therapy*
  • Melanoma-Specific Antigens
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Proteins / immunology*
  • Skin Neoplasms / mortality
  • Skin Neoplasms / therapy*
  • Survival Rate

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Melanoma-Specific Antigens
  • Neoplasm Proteins